default author photo

Robert VanderWeele

University of Pittsburgh - Medical Center (UPMC)

SCHOLARLY PAPERS

2

DOWNLOADS

110

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab as First Line Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer Patients with Eastern Cooperative Oncology Group Performance Status of 2

Number of pages: 24 Posted: 07 Aug 2023
University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Texas at Dallas - Southwestern Medical Center, University of Texas at Dallas - Southwestern Medical Center and University of Pittsburgh - Medical Center (UPMC)
Downloads 87 (765,566)

Abstract:

Loading...

Durvalumab, non-small cell lung cancer, safety, overall survival, performance status 2

2.

Brief Report: Phase Ii Clinical Trial of Atezolizumab in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Pd-1-Directed Therapy

Number of pages: 15 Posted: 01 Oct 2024
affiliation not provided to SSRN, University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pittsburgh - Medical Center (UPMC), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pittsburgh - Medical Center (UPMC), affiliation not provided to SSRN and University of Pittsburgh - Medical Center (UPMC)
Downloads 23 (1,424,331)

Abstract:

Loading...

NSCLC, Immunotherapy, atezolizumab, immunotherapy sequencing